# 肺癌筛查软件市场

> 肺癌筛查软件市场研究报告，按应用（CT筛查、MRI筛查、PET筛查、X光筛查）、按部署类型（本地部署、基于云的、混合型）、按最终用户（医院、诊断中心、研究机构、居家护理）、按软件类型（独立软件、集成软件）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 13.74%
- **2024:** $ 1.3 Billion
- **2025:** $ 1.47 Billion
- **2035:** $ 5.34 Billion
- **Key Players:** Siemens Healthineers (DE), GE Healthcare (US), Philips Healthcare (NL), Fujifilm Holdings Corporation (JP), Canon Medical Systems (JP), Hologic, Inc. (US), Carestream Health (US), Agfa-Gevaert Group (BE), RadNet, Inc. (US)

**Report ID:** MRFR/HC/39493-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/lung-cancer-screening-software-market-33064

---

## Market Summary

## **Lung Cancer Screening Software Market Overview**

As per MRFR analysis, the Lung Cancer Screening Software Market Size was estimated at 1.29 (USD Billion) in 2024. The Lung Cancer Screening Software Market Industry is expected to grow from 1.47 (USD Billion) in 2025 to 4.69 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 9.90% during the forecast period (2025 - 2034).

## **Key Lung Cancer Screening Software Market Trends Highlighted**

The Lung Cancer Screening Software Market is experiencing significant growth driven by an increasing prevalence of lung cancer worldwide. The rise in smoking rates, along with environmental factors and the aging population, has heightened the demand for early detection solutions. Advanced technologies, such as artificial intelligence and machine learning, are being integrated into screening software, enhancing the accuracy and efficiency of diagnoses.

Furthermore, the growing awareness about the benefits of early screening and preventive healthcare is influencing market expansion. Regulatory support and endorsements from health organizations further drive the adoption of these screening systems. There are ample opportunities for market players to explore innovative solutions that address the specific needs of healthcare institutions. The development of personalized screening algorithms and seamless integration with existing electronic medical records can enhance the user experience.

Emerging markets present additional growth avenues, as rising healthcare investments and increased accessibility to diagnostic tools can help establish advanced lung cancer screening programs. Collaboration with research institutions for the development of next-generation software solutions may open doors for new technology integration, leading to better patient outcomes. Recent trends indicate a shift towards remote and at-home screening solutions, driven by the demands of patients for more convenient healthcare options.

Telehealth and digital health platforms have gained traction, allowing for a broader reach of lung cancer screening services. As the healthcare landscape evolves, there is a growing focus on patient-centric approaches that emphasize early detection and continuous monitoring. The integration of big data analytics is also becoming prevalent, providing insights that enhance patient management and treatment pathways. Overall, the market is positioned for robust growth as stakeholders invest in innovative technologies that improve lung cancer outcomes through timely and accurate screening solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Lung Cancer Screening Software Market Drivers**

### **Increasing Incidence of Lung Cancer**

The rising incidence of lung cancer globally is one of the primary drivers of the Lung Cancer Screening Software Market Industry. Lung cancer remains one of the leading causes of cancer-related mortality worldwide. As healthcare systems transition towards more proactive measures, early detection methods gain traction. Screening software plays a crucial role in identifying lung cancer in its early stages, improving prognosis and survival rates.

The growing awareness among patients and healthcare professionals regarding the importance of early diagnosis propels the demand for advanced screening solutions. With increasing populations and risk factors such as smoking, pollution, and genetic predisposition, the need for effective lung cancer screening becomes imperative. The proliferation of advanced technologies, including artificial intelligence and machine learning, enhances the effectiveness of these software solutions, further driving market growth.

As healthcare policies worldwide advocate for early screening programs, the Lung Cancer Screening Software Market is expected to witness substantial development. Furthermore, the integration of such software with imaging technology, such as CT scans, aids in delivering accurate diagnostic information. This synergy between technology and healthcare continues to evolve, fostering an environment conducive to innovation and the expansion of the market as stakeholders aim to address the pressing issue of lung cancer.

### **Technological Advancements in Screening Solutions**

Technological advancements in screening software are significantly contributing to the growth of the Lung Cancer Screening Software Market Industry. Innovations such as machine learning algorithms and artificial intelligence improve the accuracy and efficiency of screening processes. These technologies help in analyzing imaging data rapidly and with higher precision, thus facilitating early detection of lung cancer and improving patient outcomes.

### **Supportive Government Initiatives**

Supportive government initiatives aimed at cancer detection and prevention are driving the growth of the Lung Cancer Screening Software Market Industry. Many governments recognize the burden of lung cancer and are implementing policies to promote regular screening programs. Public health campaigns raise awareness and encourage high-risk populations to participate in screening processes. With increased funding allocated for lung cancer research and screening technologies, the market is gaining momentum as healthcare systems evolve to prioritize preventative measures.

## **Lung Cancer Screening Software Market Segment Insights**

### **Lung Cancer Screening Software Market Application Insights**

The Lung Cancer Screening Software Market is poised for growth, with its overall market revenue projected to reach 1.0 USD Billion in 2023 and 3.2 USD Billion by 2032, reflecting the increasing need for effective screening solutions in oncology. Within this expansive market, the Application segment showcases significant diversification, as it encompasses various screening modalities, including CT Screening, MRI Screening, PET Screening, and X-ray Screening. Notably, CT Screening holds a majority holding within this segment, valued at 0.4 USD Billion in 2023 and expected to rise to 1.25 USD Billion by 2032.

This dominance stems from the high sensitivity of CT scans in detecting lung cancer at earlier stages, leading to more favorable patient outcomes. MRI Screening follows with a valuation of 0.25 USD Billion in 2023, projected to grow to 0.8 USD Billion by 2032, significant due to its ability to provide detailed images of soft tissues, aiding in the assessment of lung masses and metastatic disease.

On the other hand, PET Screening, valued at 0.15 USD Billion in 2023 with a forecast of 0.5 USD Billion by 2032, plays a crucial role in identifying metabolic activity in suspicious lesions, enhancing the diagnostic accuracy for staging lung cancer.

Lastly, X-ray Screening, which was valued at 0.2 USD Billion and is expected to reach 0.65 USD Billion by 2032, remains a traditional yet effective tool for initial lung evaluations and monitoring. The integration of these technologies within the Lung Cancer Screening Software Market highlights a continued trend toward advanced imaging solutions, driven by growing awareness and demand for early detection of lung cancer, alongside regulatory support to facilitate technological advancements. As these applications evolve, they present numerous opportunities for growth, but challenges such as high operational costs and the need for trained professionals may impact the market landscape.

Overall, the Lung Cancer Screening Software Market data indicates a robust trajectory fueled by innovation and clinical necessity, with each application segment contributing uniquely to market dynamics.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Lung Cancer Screening Software Market Deployment Type Insights**

The Lung Cancer Screening Software Market, valued at 1.0 billion USD in 2023, showcases significant growth potential across its Deployment Type segment, which includes On-Premises, Cloud-Based, and Hybrid solutions. On-premises solutions often appeal to healthcare facilities that prioritize data security, providing control over sensitive information, while Cloud-Based systems are gaining traction due to their flexibility, cost-effectiveness, and ease of access. Hybrid models combine both approaches, offering scalability and enhanced operational efficiency, catering to the diverse needs of the market.

As institutions increasingly prioritize efficient lung cancer detection and management, the preference for these deployment types reflects trends in digital healthcare transformation. The ongoing digitization in the healthcare sector and the rising demand for remote access capabilities are crucial drivers influencing the Lung Cancer Screening Software Market revenue. Factors such as regulatory compliance and data security challenges also shape the dynamic landscape, presenting both challenges and opportunities for stakeholders aiming to capitalize on the evolving Lung Cancer Screening Software Market statistics and data.

### **Lung Cancer Screening Software Market End User Insights**

The Lung Cancer Screening Software Market reflects significant growth across its end-user segment, which is pivotal in driving market dynamics. In 2023, the market was valued at 1.0 USD Billion, showcasing a robust demand for effective screening solutions in healthcare. Hospitals play a crucial role in this sector, often being the primary location for lung cancer screening due to their advanced diagnostic capabilities and access to a wide patient base. Diagnostic centers are also prominent, as they specialize in providing focused services that enhance early detection rates.

Research institutions contribute by driving innovation and facilitating studies that aim to improve screening methodologies and software efficiency. Meanwhile, home care settings are emerging as vital, especially with a shift towards patient-centered care, allowing individuals to engage in screening programs from the comfort of their homes. The combined efforts of these end users underscore a comprehensive strategy to combat lung cancer through improved screening technologies and methodologies. With the Lung Cancer Screening Software Market segmentation showing diverse applications, understanding these components is essential for identifying market growth opportunities and addressing challenges effectively.

### **Lung Cancer Screening Software Market Software Type Insights**

In 2023, the Lung Cancer Screening Software Market was valued at 1.0 billion USD and is experiencing robust growth driven by increasing awareness of lung cancer and advancements in technologies. This market is segmented into distinct software types, primarily Standalone Software and Integrated Software. Standalone Software holds significant importance for its simplicity and ease of use, making it a preferred choice for many healthcare facilities focusing exclusively on lung cancer diagnostics. On the other hand, Integrated Software is gaining traction as it offers seamless interoperability with various healthcare systems, thus enhancing overall workflow efficiency and data management.

The demand for Integrated Software is growing as providers seek to implement comprehensive solutions that streamline patient management and reporting processes. Both segments play a crucial role in shaping the landscape of lung cancer screening, as they contribute to the better accuracy of diagnostic procedures and improved patient outcomes. Overall, the Lung Cancer Screening Software Market revenue is expected to reach 3.2 billion USD by 2032, reflecting a significant growth trajectory bolstered by ongoing innovations in software technologies and a heightened need for effective lung cancer screening solutions.

### **Lung Cancer Screening Software Market Regional Insights**

The Lung Cancer Screening Software Market is projected to experience considerable growth across various regions, reflecting significant market dynamics. In 2023, North America led the market with a valuation of 0.45 USD Billion, showcasing its majority holding due to advanced healthcare infrastructure and high cancer incidence rates. Europe follows closely, valued at 0.3 USD Billion, driven by a strong emphasis on early diagnosis and innovative healthcare solutions. The Asia-Pacific (APAC) region recorded a valuation of 0.15 USD Billion in 2023, indicating a developing market eager to improve its cancer screening processes.

South America and the Middle East Africa (MEA) regions, each valued at 0.05 USD Billion, represent the smaller market segments but showcase the potential for growth due to increasing awareness and healthcare investments. These regional insights reflect the Lung Cancer Screening Software Market's segmentation, underscoring trends such as rising adoption rates, the need for technological advancements, and opportunities driven by an aging population across continents. The market figures also highlight competitiveness and the need for improvements in screening methods to enhance patient outcomes globally.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Lung Cancer Screening Software Market Key Players and Competitive Insights**

The Lung Cancer Screening Software Market is experiencing significant growth driven by the increasing incidence of lung cancer worldwide and the rising awareness of early detection methods. The competitive landscape is characterized by a multitude of players participating in the development of sophisticated software solutions aimed at improving the efficacy of lung cancer screening processes. Companies in this market focus on leveraging artificial intelligence, machine learning, and advanced imaging technologies to enhance diagnostic accuracy and patient outcomes.

Furthermore, strategic collaborations, mergers, and acquisitions among key market participants are increasingly common as they strive to broaden their service offerings and gain market share.

The emphasis on regulatory compliance and the need for integration with existing healthcare systems also shape the strategies of these companies, making the competitive environment dynamic and challenging.

### **Qure.ai**

Qure.ai has established itself as a strong contender in the Lung Cancer Screening Software Market through its innovative use of artificial intelligence to analyze medical imaging data. The company excels in developing algorithms that support radiologists by automating image analysis, thereby reducing the time required for diagnosis and increasing accuracy. Qure.ai's software not only aids in the detection of lung cancer at earlier stages but also provides actionable insights that facilitate timely clinical decisions. The company's ability to adapt to various healthcare ecosystems and integrate with existing imaging modalities enhances its market presence and strengthens its competitive edge.

Moreover, Qure.ai's commitment to continuous research and development ensures that its offerings are at the forefront of technological advancements in lung cancer screening.

### **Siemens Healthineers**

Siemens Healthineers holds a prominent position in the Lung Cancer Screening Software Market, recognized for its comprehensive portfolio of imaging solutions. The company offers advanced software that enhances imaging workflows and supports the early detection of lung cancer, thereby contributing to better patient outcomes. Siemens Healthineers is known for its reliability in providing high-quality imaging systems, integrating both hardware and software to deliver a seamless user experience for radiologists and healthcare providers. The company's strong emphasis on innovation, backed by substantial investment in research and technology, positions it well within the competitive landscape.

In addition, Siemens Healthineers benefits from a robust global distribution network, enabling it to reach a wide array of healthcare facilities and streamline the adoption of its lung cancer screening solutions across diverse markets.

### **Key Companies in the Lung Cancer Screening Software Market Include**

## **Lung Cancer Screening Software Industry Developments**

The Lung Cancer Screening Software Market is witnessing significant developments, primarily driven by advancements in technology and an increasing emphasis on early detection of lung cancer. Companies such as Qure.ai and Siemens Healthineers are focusing on integrating artificial intelligence into their screening processes to enhance accuracy. In recent months, GE Healthcare has reported notable growth in its lung cancer screening solutions, catering to a rising demand for effective diagnostic tools.

Meanwhile, IBM Watson Health and Philips Healthcare continue to enhance their portfolios by incorporating machine learning capabilities. There have also been discussions regarding strategic partnerships aimed at improving software interoperability and patient engagement in the screening process. The market is also experiencing growth resulting from increasing funding and investment in research and development, with companies like PathAI and Lunit making strides in clinical trials for software efficacy. In terms of mergers and acquisitions, there has been heightened activity among several players.

Caresyntax and Yale Biomedi have been exploring synergies for potential collaborations that would leverage their technology platforms for improved lung cancer screening outcomes. The market's valuation is expected to grow, reflecting these innovations and collaborations, which aim to address the urgent need for effective lung cancer screening solutions.

## **Lung Cancer Screening Software Market Segmentation Insights**

### **Lung Cancer Screening Software Market Application Outlook**

### **Lung Cancer Screening Software Market Deployment Type Outlook**

### **Lung Cancer Screening Software Market End User Outlook**

### **Lung Cancer Screening Software Market Software Type Outlook**

### **Lung Cancer Screening Software Market Regional Outlook**

## Market Drivers

### 医疗支出上升

各地区医疗支出的上升是肺癌筛查软件市场的重要驱动因素。随着各国在医疗保健上分配更多资源，癌症筛查技术的投资也相应增加。这一趋势在优先考虑癌症控制计划的国家尤为明显，资金被用于创新解决方案，以提高筛查的效率和准确性。医疗服务提供者愿意投资于先进的肺癌筛查软件，反映了他们改善患者护理和结果的承诺。此外，随着医疗系统认识到早期发现所带来的长期成本节约，针对有效筛查软件的需求可能会增长。因此，肺癌筛查软件市场有望受益于医疗支出上升的趋势，这支持了尖端筛查解决方案的开发和实施。

### 成像技术的进步

成像模式的技术进步，如低剂量计算机断层扫描（LDCT），正在显著影响肺癌筛查软件市场。这些创新提高了肺癌检测的准确性和效率，从而推动了能够处理和解释复杂成像数据的筛查软件的采用。将先进算法和机器学习技术集成到筛查软件中，改善了诊断能力，这对于在早期阶段识别肺癌至关重要。随着医疗机构越来越多地投资于最先进的成像技术，对兼容软件解决方案的需求预计将增长。这一趋势不仅支持更好的患者结果，还与向精准医疗的更广泛运动相一致。因此，肺癌筛查软件市场将从成像技术的持续演变及其在肺癌筛查中的应用中受益。

### 政府倡议和资金

政府的倡议和资金旨在癌症预防和早期检测，是肺癌筛查软件市场的关键驱动因素。各类健康组织和政府机构越来越认识到肺癌筛查项目的重要性，从而为该领域的研究和开发分配资源。例如，资助公共卫生宣传活动以促进肺癌意识和筛查，可以显著影响筛查软件的采用。此外，监管支持实施标准化筛查协议进一步鼓励医疗服务提供者投资于先进的软件解决方案。随着这些倡议的推进，肺癌筛查软件市场可能会经历需求激增，因为医疗系统努力遵守新指南并改善其筛查流程。

### 肺癌发病率上升

肺癌发病率的上升是肺癌筛查软件市场的主要驱动力。根据最近的统计数据，肺癌仍然是最常见的癌症之一，每年有数百万人被诊断。这一令人担忧的趋势迫切需要实施有效的筛查解决方案，以促进早期发现并改善患者的治疗结果。随着医疗服务提供者寻求增强其筛查能力，对能够分析影像数据并提供可行见解的专业软件的需求可能会增加。此外，患者对早期发现重要性的认识不断提高，预计将进一步推动市场发展，因为个人在寻求筛查选项时变得更加积极。因此，肺癌筛查软件市场有望增长，因为它满足了肺癌管理中对创新解决方案的迫切需求。

### 日益重视预防性医疗保健

对预防性医疗的日益重视是肺癌筛查软件市场的重要驱动力。随着全球医疗系统向主动措施转变，以减少疾病负担，早期发现肺癌的关注度加剧。这一范式转变鼓励采用利用先进软件识别高风险人群并促进及时干预的筛查项目。对早期发现策略的成本效益日益认可进一步支持了这一趋势，因为医疗服务提供者旨在降低与晚期肺癌相关的长期治疗成本。因此，预计对能够简化筛查过程并增强患者管理的复杂筛查软件的需求将上升。这一不断发展的格局使肺癌筛查软件市场处于有利位置，因为它与改善公共健康结果的更广泛目标相一致。

## Future Outlook

肺癌筛查软件市场预计将在2024年至2035年间以13.74%的年均增长率增长，推动因素包括技术进步、意识提高和医疗支出增加。

**New opportunities:**

- 集成基于人工智能的诊断工具以提高准确性

到2035年，市场预计将强劲增长，受创新和战略合作的推动。

## Segment Insights

### 按应用：CT筛查（最大）与X光筛查（增长最快）

在肺癌筛查软件市场中，应用细分市场主要由CT筛查主导，由于其在临床环境中的有效性和普遍性，保持了相当大的市场份额。X光筛查迅速崛起，吸引了寻求成本效益的初步诊断工具的医疗服务提供者。这些技术的采用反映了肺癌筛查中向更标准化实践的转变，从而显著影响了整体市场动态。

CT筛查（主导）与MRI筛查（新兴）

CT筛查因其非侵入性和高敏感性在早期癌症检测中继续主导肺癌筛查领域。尽管MRI筛查仍在发展中，但因其详细的成像能力，尤其是在复杂病例中，正逐渐受到医疗专业人士的关注。MRI提供增强的软组织对比度，使其成为CT旁边一个重要但不太传统的选择。这两种筛查方法在现代诊断中都是不可或缺的，CT在广泛应用中领先，而MRI则因其在特定肺癌评估临床场景中的潜力而受到认可。

### 按部署类型：基于云的（最大）与本地部署（增长最快）

肺癌筛查软件市场正在经历显著的部署类型分化，其中基于云的解决方案占据了最大的市场份额。该细分市场受益于其灵活性，使医疗机构能够优化成本并提高用户的可及性。相反，内部部署解决方案由于能够提供对数据和安全性的更多控制，正在迅速获得关注，特别吸引那些优先考虑这些因素的大型医疗机构。

增长趋势表明，尽管基于云的解决方案占主导地位，但随着组织寻求将敏感信息保留在本地基础设施中，对内部部署软件的需求正在加速。混合部署也在出现，结合了云和内部部署解决方案的优点，提供了一种平衡的数据管理方法，这进一步复杂化了竞争格局，偏向于能够提供定制解决方案的供应商。

基于云的（主导）与本地部署的（新兴）

基于云的肺癌筛查软件市场细分以其高可扩展性和成本效益为特征，使其对广泛的医疗服务提供者具有吸引力。这种部署类型使得更新和远程访问变得容易，促进了医疗专业人员之间的协作。相比之下，虽然本地部署细分目前被归类为新兴市场，但由于对数据安全和合规性的日益关注，它正在获得动力。医疗机构越来越倾向于选择本地解决方案，以保持对其数据环境的控制。这一趋势进一步体现在对混合解决方案日益增长的兴趣上，混合解决方案提供了一个引人注目的替代方案，使组织能够利用云的优势，同时在内部保留敏感数据，以满足不同医疗环境的特定需求。

### 按最终用户：医院（最大）与诊断中心（增长最快）

在肺癌筛查软件市场中，医院作为主要的医疗保健提供者占据了最大的市场份额。它们配备了先进的诊断技术，并拥有管理全面肺癌筛查项目所需的关键基础设施。此外，庞大的患者流量和所需的后续护理巩固了它们在这一细分市场中的地位。相反，诊断中心正经历快速增长，利用日益增长的对专业肺癌筛查的需求，以及提高意识和早期检测的努力。它们专注的服务和高效性吸引了更多寻求便捷和高效筛查选项的患者。

医院（主导）与研究机构（新兴）

在当前的肺癌筛查软件市场中，医院被视为主导者，因为它们拥有丰富的资源和成熟的患者护理协议。它们利用强大的筛查软件系统，支持早期诊断和治疗计划。相比之下，研究机构代表了一个新兴的细分市场，受到创新和临床试验的推动，旨在完善肺癌筛查技术。它们在开发和验证旨在提高肺癌检测准确性和有效性的新方法方面发挥着至关重要的作用，使其成为推动研究进展的不可或缺的合作伙伴，同时逐渐在市场中获得重要地位。

### 按软件类型：独立软件（最大）与集成软件（增长最快）

肺癌筛查软件市场的特点是独立软件占据了显著的市场份额。由于其简单性和直接的功能，专门针对肺癌诊断，这一类别传统上一直是许多医疗服务提供者的首选。相比之下，集成软件正在迅速获得青睐，作为一种更受欢迎的解决方案，提供与现有健康信息技术生态系统的无缝互操作性，提供更全面的患者管理和诊断准确性。

软件类型：独立（主导）与集成（新兴）

独立软件长期以来被视为肺癌筛查的主导产品，主要由于其针对性的功能，这些功能专门设计用于肺部疾病的成像和分析。该软件允许采用集中和高效的筛查方法，使其成为许多放射科医生和医疗机构的首选。另一方面，集成软件作为强有力的竞争者正在崛起，其特点是能够在更广泛的电子健康记录（EHR）系统中工作。这一能力不仅增强了数据共享和可及性，还支持全面的患者护理，从而与当前向集成医疗解决方案的趋势相一致。

## Regional Market Share Analysis

### 北美：引领创新与采用

北美是肺癌筛查软件最大的市场，约占全球市场份额的45%。该地区受益于先进的医疗基础设施、高度的肺癌风险意识以及支持早期检测的政府法规。肺癌的日益普遍和对预防性医疗的推动是重要的增长驱动因素，同时影像学和软件解决方案的技术进步也在推动市场发展。

美国是该市场的主要贡献者，GE医疗和霍洛吉克公司等关键企业引领着这一领域。竞争格局的特点是主要公司之间持续的创新和合作。加拿大也发挥着重要作用，专注于增强筛查项目并整合先进技术以改善患者结果。成熟的医疗系统的存在进一步支持了市场的增长。

### 欧洲：监管支持与增长

欧洲的肺癌筛查软件市场正在经历显著增长，约占全球市场份额的30%。该地区的增长受到旨在提高癌症筛查率和早期检测的严格法规的推动。欧盟和国家卫生组织的倡议正在催化对医疗技术的投资，从而增强肺癌筛查解决方案在成员国的采用。

该地区的主要国家包括德国、法国和英国，医疗系统正日益整合先进的筛查技术。西门子医疗和飞利浦医疗等关键企业积极参与开发符合监管标准的创新解决方案。竞争格局的特点是技术提供商与医疗机构之间的合作，旨在改善患者获取筛查服务的机会。

### 亚太地区：快速增长与采用

亚太地区正迅速崛起为肺癌筛查软件的重要市场，约占全球市场份额的20%。该地区的增长受到对肺癌意识的提高、医疗支出的增加以及政府倡导早期检测的举措的推动。中国和印度等国的肺癌病例激增，促使对筛查技术和预防性医疗措施的更大关注。

中国是该地区最大的市场，越来越多的医疗机构正在采用先进的筛查解决方案。竞争格局中既有本地企业也有国际企业，包括富士胶卷控股和佳能医疗系统，他们正在投资研发以满足该地区的独特需求。庞大的人口和日益城市化的趋势进一步推动了对有效肺癌筛查解决方案的需求。

### 中东和非洲：新兴市场面临挑战

中东和非洲地区的肺癌筛查软件市场正在逐步发展，目前约占全球市场份额的5%。增长主要受到对肺癌意识的提高和改善医疗基础设施需求的推动。然而，先进医疗技术的有限获取和各国之间不同的监管框架等挑战阻碍了市场的快速扩展。各国政府开始认识到早期检测的重要性，这预计将催化未来的增长。

南非和阿联酋等国在采用肺癌筛查技术方面走在前列，推出旨在提升医疗服务的举措。竞争格局仍在演变中，本地和国际企业纷纷进入市场。各公司专注于合作与协作，以改善筛查解决方案的获取，并应对该地区面临的独特医疗挑战。

## Competitive Benchmarking

肺癌筛查软件市场目前的特点是动态的竞争格局，受到技术进步和对早期肺癌检测日益重视的驱动。西门子医疗（德国）、GE医疗（美国）和飞利浦医疗（荷兰）等主要参与者处于前沿，各自采用不同的策略来增强市场定位。西门子医疗（德国）专注于通过开发先进的成像技术来推动创新，而GE医疗（美国）则强调与医疗服务提供者的合作以扩大其影响力。飞利浦医疗（荷兰）则在数字化转型上进行了大量投资，将人工智能能力整合到其筛查软件中，以提高诊断准确性。这些策略共同促成了一个日益以技术创新和战略合作为中心的竞争环境。

在商业策略方面，公司正在本地化制造和优化供应链，以提高运营效率。市场结构看起来适度分散，几家主要参与者在各个细分市场上施加影响。这种分散性允许提供多样化的产品，但霍洛吉克公司（美国）和富士胶卷控股公司（日本）等主要公司的集体影响是显著的，因为它们推动了产品开发和市场扩展的趋势。

在2025年8月，霍洛吉克公司（美国）宣布与一家领先的远程医疗提供商建立战略合作伙伴关系，以增强远程肺癌筛查能力。这一举措尤其值得注意，因为它与对远程医疗解决方案日益增长的需求相一致，使得筛查服务的可及性更广。通过将其软件与远程医疗平台整合，霍洛吉克旨在简化筛查过程，可能提高早期检测率并改善患者结果。

在2025年9月，富士胶卷控股公司（日本）推出了一款新的人工智能驱动的肺癌筛查软件，增强了图像分析和诊断精度。这一发展具有重要意义，因为它反映了公司利用人工智能改善临床工作流程的承诺。这款软件的推出不仅使富士胶卷在创新方面处于领先地位，还满足了医疗行业对准确和高效诊断工具日益增长的需求。

在2025年10月，GE医疗（美国）通过与亚洲一家知名医疗机构建立合资企业，扩大了其全球足迹。这一战略举措表明GE专注于区域扩展，并意图进入肺癌筛查日益受到重视的新兴市场。通过在亚洲建立存在，GE医疗可能会增强其竞争优势，并满足日益增长的需要先进筛查解决方案的患者群体。

截至2025年10月，肺癌筛查软件市场的竞争趋势受到数字化、可持续性和人工智能整合的强烈影响。战略联盟变得越来越重要，因为公司寻求增强其技术能力并扩大市场覆盖。展望未来，竞争差异化似乎将从传统的基于价格的竞争转向对创新、技术进步和供应链可靠性的关注。这一转变表明，优先考虑研发和战略合作伙伴关系的公司可能会在这个快速发展的市场中脱颖而出。

## Recent News & Developments

肺癌筛查软件市场正在经历显著的发展，主要受到技术进步和对早期发现肺癌日益重视的推动。像 Qure.ai 和西门子医疗这样的公司正专注于将人工智能整合到他们的筛查过程中，以提高准确性。最近，GE 医疗报告了其肺癌筛查解决方案的显著增长，以满足对有效诊断工具日益增长的需求。

与此同时，IBM Watson Health 和飞利浦医疗继续通过整合机器学习能力来增强他们的产品组合。关于旨在改善软件互操作性和患者参与筛查过程的战略合作伙伴关系的讨论也在进行中。市场还因对研究和开发的资金和投资增加而经历增长，像 PathAI 和 Lunit 这样的公司在软件有效性临床试验中取得了进展。在并购方面，几家参与者之间的活动也有所增加。

Caresyntax 和耶鲁生物医学正在探索协同效应，以便进行潜在的合作，利用他们的技术平台改善肺癌筛查结果。市场的估值预计将增长，反映这些创新和合作，旨在满足对有效肺癌筛查解决方案的迫切需求。

## Report Scope

| 2024年市场规模 | 1.295（亿美元） |
| --- | --- |
| 2025年市场规模 | 1.473（亿美元） |
| 2035年市场规模 | 5.338（亿美元） |
| 复合年增长率（CAGR） | 13.74%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 亿美元 |
| 关键公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 关键市场机会 | 人工智能的整合提高了肺癌筛查软件市场的诊断准确性。 |
| 关键市场动态 | 对早期检测的需求上升推动了肺癌筛查软件解决方案的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 肺癌筛查软件市场的当前估值是多少？**
A: 截至2024年，市场估值为12.95亿美元。

**Q: 到2035年，肺癌筛查软件市场的预计市场规模是多少？**
A: 预计到2035年，市场估值将达到53.38亿美元。

**Q: 在2025年至2035年的预测期内，肺癌筛查软件市场的预期CAGR是多少？**
A: 在此期间，市场的预期CAGR为13.74%。

**Q: 在肺癌筛查软件市场中，哪些公司被视为关键参与者？**
A: 主要参与者包括西门子医疗、GE医疗、飞利浦医疗和富士胶片控股公司。

**Q: 肺癌筛查软件市场的主要应用领域是什么？**
A: 主要应用领域包括CT筛查、MRI筛查、PET筛查和X光筛查。

**Q: 部署类型细分在市场估值方面是如何划分的？**
A: 在2024年，本地部署部分的估值为5.18亿美元，而基于云和混合部分的估值分别为3.88亿美元和3.89亿美元。

**Q: 肺癌筛查软件市场中，医院作为最终用户的市场估值是多少？**
A: 在2024年，医院的市场估值为5.18亿美元。

**Q: 到2035年，集成软件领域的预期增长是多少？**
A: 集成软件部门预计将从2024年的7.77亿美元增长到2035年的31.84亿美元。

**Q: 肺癌筛查软件市场中诊断中心的市场估值是多少？**
A: 在2024年，诊断中心的市场估值为3.89亿美元。

**Q: 家庭护理市场与其他终端用户相比如何？**
A: 2024年，居家护理环境的市场估值为1.3亿美元，低于医院和诊断中心。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/lung-cancer-screening-software-market-33064*